8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Apr 27, 2026·SEC
Armata Pharmaceuticals, Inc.(ARMP)Earnings, Financials & Key Ratios
ARMP•AMEX
Price updated Jun 19, 2026
AboutArmata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.Show more
- Revenue$5M-5.2%
- EBITDA-$30M+27.8%
- Net Income-$174M-818.8%
- EPS (Diluted)-4.80-823.1%
- Gross Margin68.78%+112.2%
- EBITDA Margin-605.44%+23.8%
- Operating Margin-636.66%+22.4%
- Net Margin-3544.03%-869.4%
ARMP Key Insights
Armata Pharmaceuticals, Inc. (ARMP) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 42.9%
✗Weaknesses
- ✗Profits declining 50.9% over 5 years
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ARMP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ARMP Price & Volume
Armata Pharmaceuticals, Inc. (ARMP) stock price & volume — 10-year historical chart
Loading chart...
ARMP Growth Metrics
Armata Pharmaceuticals, Inc. (ARMP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years26.29%
5 Years42.9%
3 Years-3.8%
TTM-37.05%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-66241.31%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1349.63%
Return on Capital
10 Years-86.47%
5 Years-55.56%
3 Years-59.7%
Last Year-58.84%
ARMP Recent Earnings
Armata Pharmaceuticals, Inc. (ARMP) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 8/12 qtrs (73%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.39-2.6%
$0.38
Rev
$789,000+6.6%
$740,000
Q2 2026
Mar 31, 2026Metric
Actual
Est
EPS
$3.16-731.6%
$0.38
Rev
$789,000+6.6%
$740,000
Q2 2026
Mar 25, 2026Metric
Actual
Est
EPS
$0.51-168.4%
$0.19
Rev
$1M+48.6%
$740,000
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.42+0.0%
$0.42
Rev
$1M+56.6%
$740,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.39vs $0.38-2.6% | $789,000vs $740,000+6.6% |
| Q2 2026 | Mar 31, 2026 | $3.16vs $0.38-731.6% | $789,000vs $740,000+6.6% |
| Q2 2026 | Mar 25, 2026 | $0.51vs $0.19-168.4% | $1Mvs $740,000+48.6% |
| Q4 2025 | Nov 12, 2025 | $0.42vs $0.42+0.0% | $1Mvs $740,000+56.6% |
Based on last 12 quarters of dataView full earnings history →
ARMP Peer Comparison
Armata Pharmaceuticals, Inc. (ARMP) competitors in Microbiome and Phage Therapeutics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PHGE | 1.35B | 0.52 | -0.02 | -6.94% | ||||
 LSTA | 32.05M | 3.52 | -1.84 | -83% | -96.18% | -103.54% | ||
 SIGA | 309.85M | 4.32 | 13.09 | -31.8% | 21.61% | 10.62% | 0.00 | |
 ACXP | 2.44M | 1.54 | -0.29 | -153.93% | ||||
 INNV | 1.22B | 8.97 | -40.77 | 11.76% | -2.35% | -8.18% | 0.38 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 ADMA | 1.93B | 8.31 | 13.85 | 19.63% | 32.43% | 38.97% | 0.17 |
Compare ARMP vs Peers
Armata Pharmaceuticals, Inc. (ARMP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ARMP Income Statement
Armata Pharmaceuticals, Inc. (ARMP) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 115K | 0 | 0 | 823K | 4.47M | 5.51M | 4.53M | 5.17M | 4.9M | 2.96M |
Revenue Growth % | -55.77% | -100% | - | - | 443.62% | 23.11% | -17.77% | 14.24% | -5.22% | -37.05% |
Cost of Goods Sold | 374K | 1.35M | 1.35M | 14.44M | 20.02M | 35.02M | 972K | 34.43M | 1.53M | 823K |
COGS % of Revenue | 325.22% | - | - | 1755.04% | 447.36% | 635.75% | 21.46% | 665.37% | 31.22% | - |
Gross Profit | -259K▲ 0% | -1.35M▼ 421.6% | -1.35M▲ 0.0% | -13.62M▼ 908.2% | -15.54M▼ 14.1% | -29.51M▼ 89.9% | 3.56M▲ 112.1% | -29.25M▼ 922.4% | 3.37M▲ 111.5% | 2.13M▲ 0% |
Gross Margin % | -225.22% | - | - | -1655.04% | -347.36% | -535.75% | 78.54% | -565.37% | 68.78% | 72.18% |
Gross Profit Growth % | -137.61% | -421.62% | 0% | -908.22% | -14.1% | -89.88% | 112.05% | -922.38% | 111.53% | - |
Operating Expenses | 16.27M | 9.54M | 17.74M | 7.97M | 8.28M | 7.44M | 44.45M | 13.18M | 34.59M | 39.36M |
OpEx % of Revenue | 14148.7% | - | - | 967.92% | 185.09% | 135.02% | 981.39% | 254.81% | 705.44% | - |
Selling, General & Admin | 7.59M | 5.7M | 7.91M | 7.97M | 8.28M | 7.44M | 10.68M | 13.18M | 12.41M | 12.62M |
SG&A % of Revenue | 6600% | - | - | 967.92% | 185.09% | 135.02% | 235.75% | 254.81% | 253.04% | - |
Research & Development | 2.88M | 4.89M | 9.82M | 14.44M | 20.02M | 35.02M | 33.77M | 34.43M | 23.72M | 24.4M |
R&D % of Revenue | 2505.22% | - | - | 1755.04% | 447.36% | 635.75% | 745.64% | 665.37% | 483.63% | - |
Other Operating Expenses | 6K | -1.4M | 0 | -14.44M | -20.02M | -35.02M | 0 | -34.43M | -1.53M | -823K |
Operating Income | -16.16M▲ 0% | -12.52M▲ 22.5% | -19.09M▼ 52.4% | -21.59M▼ 13.1% | -23.82M▼ 10.4% | -36.95M▼ 55.1% | -40.89M▼ 10.7% | -42.44M▼ 3.8% | -31.22M▲ 26.4% | -37.23M▲ 0% |
Operating Margin % | -14048.7% | - | - | -2622.96% | -532.45% | -670.77% | -902.85% | -820.18% | -636.66% | -1258.55% |
Operating Income Growth % | 30.89% | 22.48% | -52.42% | -13.09% | -10.35% | -55.09% | -10.67% | -3.78% | 26.43% | - |
EBITDA | -15.78M | -11.17M | -17.74M | -20.47M | -22.65M | -36.05M | -39.92M | -41.11M | -29.69M | -35.62M |
EBITDA Margin % | -13723.48% | - | - | -2487.61% | -506.33% | -654.58% | -881.39% | -794.57% | -605.44% | -1204.09% |
EBITDA Growth % | 31.41% | 29.2% | -58.76% | -15.42% | -10.65% | -59.16% | -10.72% | -2.99% | 27.78% | 8.71% |
D&A (Non-Cash Add-back) | 374K | 1.35M | 1.35M | 1.11M | 1.17M | 892K | 972K | 1.32M | 1.53M | 1.61M |
EBIT | -10.36M | -10.89M | -18.55M | -21.55M | -23.09M | -36.95M | -66.42M | -42.44M | -31.22M | -163.06M |
Net Interest Income | 0 | 0 | -835K | -600K | -59K | 0 | -2.45M | -10.04M | -16.2M | -18.16M |
Interest Income | 0 | 0 | 96K | 28K | 5K | 29K | 179K | 697K | 388K | 389K |
Interest Expense | 0 | 0 | 931K | 628K | 64K | 29K | 2.63M | 10.74M | 16.59M | 18.55M |
Other Income/Expense | 2.02M | 956K | -390K | -594K | 667K | 29K | -28.16M | 23.52M | -142.58M | -245.39M |
Pretax Income | -14.14M▲ 0% | -16.7M▼ 18.1% | -19.48M▼ 16.6% | -22.18M▼ 13.9% | -23.16M▼ 4.4% | -36.92M▼ 59.4% | -69.05M▼ 87.0% | -18.92M▲ 72.6% | -173.8M▼ 818.8% | -282.61M▲ 0% |
Pretax Margin % | -12295.65% | - | - | -2695.14% | -517.55% | -670.24% | -1524.51% | -365.6% | -3544.03% | -9554.23% |
Income Tax | -1.3M | -328K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 9.21% | 1.96% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -12.84M▲ 0% | -12.11M▲ 5.7% | -19.48M▼ 60.9% | -22.18M▼ 13.9% | -23.16M▼ 4.4% | -36.92M▼ 59.4% | -69.05M▼ 87.0% | -18.92M▲ 72.6% | -173.8M▼ 818.8% | -282.61M▲ 0% |
Net Margin % | -11163.48% | - | - | -2695.14% | -517.55% | -670.24% | -1524.51% | -365.6% | -3544.03% | -9554.23% |
Net Income Growth % | 31.85% | 5.67% | -60.85% | -13.87% | -4.39% | -59.43% | -87.03% | 72.6% | -818.79% | -66241.31% |
Net Income (Continuing) | -12.84M | -16.7M | -19.48M | -22.18M | -23.16M | -36.92M | -69.05M | -18.92M | -173.8M | -282.61M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -27.34▲ 0% | -8.90▲ 67.4% | -2.43▲ 72.7% | -1.35▲ 44.4% | -0.96▲ 28.9% | -1.08▼ 12.5% | -1.91▼ 76.9% | -0.52▲ 72.8% | -4.80▼ 823.1% | -7.74▲ 0% |
EPS Growth % | 92.09% | 67.45% | 72.7% | 44.44% | 28.89% | -12.5% | -76.85% | 72.77% | -823.08% | -1349.63% |
EPS (Basic) | -28.14 | -8.90 | -2.43 | -1.35 | -0.96 | -1.08 | -1.91 | -0.52 | -4.80 | - |
Diluted Shares Outstanding | 456.24K | 332.34K | 7.83M | 16.42M | 24.1M | 34.29M | 36.08M | 36.16M | 36.24M | 36.53M |
Basic Shares Outstanding | 456.24K | 332.34K | 7.83M | 16.42M | 24.1M | 34.29M | 36.08M | 36.16M | 36.24M | 36.53M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ARMP Balance Sheet
Armata Pharmaceuticals, Inc. (ARMP) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 5.38M | 8.41M | 6.66M | 10.85M | 14.99M | 27.05M | 19.15M | 11.31M | 10.67M | 5.95M |
Cash & Short-Term Investments | 5.13M | 8.16M | 6.03M | 9.65M | 10.29M | 14.85M | 13.52M | 9.29M | 8.69M | 4.75M |
Cash Only | 5.13M | 8.16M | 6.03M | 9.65M | 10.29M | 14.85M | 13.52M | 9.29M | 8.69M | 4.75M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 561K | 2.99M | 1.94M | 3.36M | 744K | 472K | 47K |
Days Sales Outstanding | - | - | - | 248.8 | 243.85 | 128.29 | 271.03 | 52.49 | 35.13 | 106.3 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 253K | 0 | 622K | 0 | 0 | 10.26M | 2.27M | 1.27M | 1.51M | 1.15M |
Total Non-Current Assets | 5.75M | 3.48M | 18.8M | 28.67M | 54.77M | 80.83M | 79.21M | 75.13M | 66.21M | 63.85M |
Property, Plant & Equipment | 816K | 503K | 4.21M | 12.84M | 38.07M | 46.65M | 57.28M | 54.93M | 46.1M | 45.17M |
Fixed Asset Turnover | 0.14x | - | - | 0.06x | 0.12x | 0.12x | 0.08x | 0.09x | 0.11x | 0.06x |
Goodwill | 0 | 0 | 3.49M | 3.49M | 3.49M | 3.49M | 3.49M | 3.49M | 3.49M | 3.49M |
Intangible Assets | 4.94M | 2.98M | 10.26M | 10.26M | 10.26M | 10.26M | 10.26M | 10.26M | 10.26M | 10.26M |
Long-Term Investments | 0 | 800K | 700K | 1.2M | 0 | 5.96M | 0 | 5.48M | 5.39M | 9.51M |
Other Non-Current Assets | 0 | 136K | 135K | -2.13M | 2.96M | 2.43M | 8.19M | 975K | 973K | 813K |
Total Assets | 11.14M▲ 0% | 11.89M▲ 6.7% | 25.45M▲ 114.1% | 39.52M▲ 55.3% | 69.77M▲ 76.6% | 107.88M▲ 54.6% | 98.36M▼ 8.8% | 86.44M▼ 12.1% | 76.88M▼ 11.1% | 69.8M▲ 0% |
Asset Turnover | 0.01x | - | - | 0.02x | 0.06x | 0.05x | 0.05x | 0.06x | 0.06x | 0.04x |
Asset Growth % | -38.79% | 6.72% | 114.11% | 55.26% | 76.56% | 54.62% | -8.82% | -12.12% | -11.05% | -65.34% |
Total Current Liabilities | 1.97M | 2.57M | 4.88M | 6.71M | 4.81M | 24.87M | 16.46M | 48.25M | 8.95M | 9.23M |
Accounts Payable | 578K | 729K | 547K | 956K | 1.14M | 6.03M | 1.58M | 766K | 921K | 660K |
Days Payables Outstanding | 564.09 | 196.95 | 147.78 | 24.16 | 20.75 | 62.9 | 595.19 | 8.12 | 219.57 | 424.21 |
Short-Term Debt | 0 | 0 | 1.31M | 722K | 0 | 17.01M | 0 | 38.95M | 4.56M | 4.59M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 340K | 1.35M | 1.7M | 1.94M | 0 | 0 | 1.29M | 529K | 3.46M | 3.98M |
Current Ratio | 2.74x | 3.27x | 1.36x | 1.62x | 3.11x | 1.09x | 1.16x | 0.23x | 1.19x | 0.64x |
Quick Ratio | 2.74x | 3.27x | 1.36x | 1.62x | 3.11x | 1.09x | 1.16x | 0.23x | 1.19x | 0.64x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -317.9 |
Total Non-Current Liabilities | 1.44M | 841K | 5.98M | 13.95M | 39.56M | 46.92M | 113.97M | 86.21M | 286.53M | 372.16M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 82.31M | 55.44M | 256.92M | 342.9M |
Capital Lease Obligations | 0 | 0 | 1.55M | 10.88M | 36.48M | 31.8M | 28.58M | 27.69M | 26.53M | 106.68M |
Deferred Tax Liabilities | 1.15M | 819K | 3.08M | 3.08M | 3.08M | 15.12M | 3.08M | 3.08M | 3.08M | 12.31M |
Other Non-Current Liabilities | 292K | 22K | 1.35M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 3.41M | 3.41M | 10.86M | 20.66M | 44.37M | 71.8M | 130.43M | 134.46M | 295.48M | 381.39M |
Total Debt | 0 | 0 | 2.86M | 13.15M | 37.99M | 48.81M | 120.37M | 126.52M | 288.02M | 373.67M |
Net Debt | -5.13M | -8.16M | -3.17M | 3.5M | 27.7M | 33.96M | 106.85M | 117.22M | 279.33M | 368.92M |
Debt / Equity | - | - | 0.20x | 0.70x | 1.50x | 1.35x | - | - | - | -1.20x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -10.49x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -10.36x |
Interest Coverage | - | - | -19.92x | -34.32x | -360.80x | -1274.00x | -25.29x | -3.95x | -1.88x | -8.79x |
Total Equity | 7.73M▲ 0% | 8.47M▲ 9.6% | 14.59M▲ 72.2% | 18.86M▲ 29.2% | 25.4M▲ 34.7% | 36.08M▲ 42.1% | -32.06M▼ 188.9% | -48.02M▼ 49.8% | -218.6M▼ 355.2% | -311.59M▲ 0% |
Equity Growth % | -20.49% | 9.61% | 72.21% | 29.22% | 34.68% | 42.06% | -188.87% | -49.76% | -355.23% | -972.86% |
Book Value per Share | 16.94 | 25.50 | 1.86 | 1.15 | 1.05 | 1.05 | -0.89 | -1.33 | -6.03 | -8.53 |
Total Shareholders' Equity | 7.73M | 8.47M | 14.59M | 18.86M | 25.4M | 36.08M | -32.06M | -48.02M | -218.6M | -311.59M |
Common Stock | 95K | 323K | 99K | 187K | 271K | 361K | 361K | 362K | 364K | 366K |
Retained Earnings | -394.21M | -406.32M | -157.52M | -179.7M | -202.86M | -239.77M | -308.82M | -327.74M | -501.53M | -616.88M |
Treasury Stock | -401.84M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -11.14M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ARMP Cash Flow Statement
Armata Pharmaceuticals, Inc. (ARMP) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -9.19M | -9.38M | -15.58M | -18.27M | -23.57M | -32.48M | -47.42M | -37.55M | -25.76M | -23.96M |
Operating CF Margin % | -7993.04% | - | - | -2219.93% | -526.93% | -589.71% | -1047.1% | -725.76% | -525.35% | - |
Operating CF Growth % | 13.19% | -2.07% | -66.08% | -17.25% | -29.04% | -37.78% | -46% | 20.82% | 31.39% | 120.18% |
Net Income | -12.84M | -12.11M | -19.48M | -22.18M | -23.16M | -36.92M | -69.05M | -18.92M | -173.8M | -282.61M |
Depreciation & Amortization | 374K | 389K | 1.35M | 1.11M | 1.17M | 892K | 972K | 1.32M | 1.53M | 1.61M |
Stock-Based Compensation | 700K | 478K | 4.27M | 3.48M | 2.88M | 3.1M | 938K | 2.89M | 2.61M | 2.9M |
Deferred Taxes | -1.3M | -328K | -454K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 4.33M | 1.84M | 918K | 196K | -1.25M | 0 | 29.36M | -20.75M | 145.31M | 253.45M |
Working Capital Changes | -457K | 345K | -2.19M | -874K | -3.22M | 439K | -9.65M | -2.1M | -1.41M | 684K |
Change in Receivables | 381K | 0 | 0 | -467K | -2.43M | 1.05M | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -838K | 343K | -1.37M | 544K | 184K | 3.67M | 39K | -3.75M | -334K | -133K |
Cash from Investing | -58K | -44K | 2.88M | -824K | -1.3M | -2.21M | -8.13M | -1.88M | -542K | -506K |
Capital Expenditures | -58K | -44K | -131K | -824K | -1.3M | -2.21M | -8.14M | -1.88M | -542K | -506K |
CapEx % of Revenue | 50.43% | - | - | 100.12% | 29.15% | 40.14% | 179.82% | 36.32% | 11.05% | 17.11% |
Acquisitions | 0 | 65K | 3.01M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -1.91M | 9.69M | 0 | 0 | 0 | 0 | 10K | 0 | 0 | 0 |
Cash from Financing | 8.67M | 12.45M | 8.97M | 23.21M | 25.52M | 44.02M | 53.99M | 34.96M | 25.61M | 16.27M |
Debt Issued (Net) | -815K | 0 | 0 | 717K | 0 | 0 | 54.03M | 34.89M | 25M | 15M |
Equity Issued (Net) | 9.35M | 12.25M | 9.97M | 22.89M | 26.32M | 44.52M | 5K | 130K | 658K | 1.36M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 133K | 203K | -1M | -400K | -801K | -500K | -43K | -61K | -46K | -95K |
Net Change in Cash | -579K▲ 0% | 3.02M▲ 622.5% | -3.73M▼ 223.3% | 4.12M▲ 210.3% | 639K▼ 84.5% | 4.56M▲ 614.2% | -1.57M▼ 134.4% | -4.47M▼ 185.0% | -693K▲ 84.5% | -8.2M▲ 0% |
Free Cash Flow | -9.25M▲ 0% | -9.43M▼ 1.9% | -15.71M▼ 66.7% | -19.09M▼ 21.5% | -24.88M▼ 30.3% | -34.69M▼ 39.4% | -55.57M▼ 60.2% | -39.43M▲ 29.0% | -26.3M▲ 33.3% | -24.47M▲ 0% |
FCF Margin % | -8043.48% | - | - | -2320.05% | -556.08% | -629.85% | -1226.92% | -762.08% | -536.4% | -827.28% |
FCF Growth % | 14.89% | -1.9% | -66.7% | -21.52% | -30.3% | -39.44% | -60.17% | 29.04% | 33.29% | 32.54% |
FCF per Share | -20.27 | -28.36 | -2.01 | -1.16 | -1.03 | -1.01 | -1.54 | -1.09 | -0.73 | -0.67 |
FCF Conversion (FCF/Net Income) | 0.72x | 0.77x | 0.80x | 0.82x | 1.02x | 0.88x | 0.69x | 1.99x | 0.15x | 0.09x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ARMP Key Ratios
Armata Pharmaceuticals, Inc. (ARMP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -147.11% | -149.46% | -168.89% | -132.62% | -104.65% | -120.1% | -3439.35% | - | - | 162.59% |
Return on Invested Capital (ROIC) | -326.87% | -644.24% | -243.9% | -95.85% | -47.36% | -45% | -42.35% | -44.21% | -36.04% | -43.71% |
Gross Margin | -225.22% | - | - | -1655.04% | -347.36% | -535.75% | 78.54% | -565.37% | 68.78% | 72.18% |
Net Margin | -11163.48% | - | - | -2695.14% | -517.55% | -670.24% | -1524.51% | -365.6% | -3544.03% | -9554.23% |
Debt / Equity | - | - | 0.20x | 0.70x | 1.50x | 1.35x | - | - | - | -1.20x |
Interest Coverage | - | - | -19.92x | -34.32x | -360.80x | -1274.00x | -25.29x | -3.95x | -1.88x | -8.79x |
FCF Conversion | 0.72x | 0.77x | 0.80x | 0.82x | 1.02x | 0.88x | 0.69x | 1.99x | 0.15x | 0.09x |
Revenue Growth | -55.77% | -100% | - | - | 443.62% | 23.11% | -17.77% | 14.24% | -5.22% | -37.05% |
Related:ARMP Dividend History·ARMP Revenue History·ARMP Price History·ARMP P/E History·ARMP Financial Ratios·ARMP Institutional Holders
ARMP SEC Filings & Documents
Armata Pharmaceuticals, Inc. (ARMP) SEC filings — annual & quarterly reports (10-K, 10-Q)
ARMP Frequently Asked Questions
Armata Pharmaceuticals, Inc. (ARMP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Armata Pharmaceuticals, Inc. (ARMP) reported $3.0M in revenue for fiscal year 2025. This represents a 2858% increase from $0.1M in 1993.
Armata Pharmaceuticals, Inc. (ARMP) saw revenue decline by 5.2% over the past year.
Armata Pharmaceuticals, Inc. (ARMP) reported a net loss of $282.6M for fiscal year 2025.
Dividend & Returns
Armata Pharmaceuticals, Inc. (ARMP) had negative free cash flow of $24.5M in fiscal year 2025, likely due to heavy capital investments.